Drug Profile


Alternative Names: Atorvastatin/ramipril/S-metoprolol; Metpure AR; Ramipril/atorvastatin/S-metoprolol; Ramipril/S-metoprolol/atorvastatin; S-metoprolol/atorvastatin/ramipril; S-metoprolol/ramipril/atorvastatin

Latest Information Update: 09 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Emcure Pharmaceuticals
  • Class Antihyperlipidaemics; Antihypertensives; Antimigraines; Class II antiarrhythmics; Fatty acids; Heart failure therapies; Heptanoic acids; Heterocyclic bicyclo compounds; Propanolamines; Pyrroles; Small molecules
  • Mechanism of Action ACE inhibitors; Beta 1 adrenergic receptor antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension; Hypercholesterolaemia

Most Recent Events

  • 09 Oct 2015 No recent reports on development identified - Phase-III for Essential hypertension (Treatment-naive) in India (PO)
  • 10 Aug 2015 Launched for Essential hypertension in India (PO) before August 2015
  • 10 Aug 2015 Launched for Hypercholesterolaemia in India (PO) before August 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top